[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "The most likely diagnosis is Primary CNS Lymphoma (PCNSL).\n\nThis conclusion is based on several key findings:\n1. Severely immunocompromised patient (CD4 count <100)\n2. EBV-positive CSF (EBV is strongly associated with PCNSL in HIV patients)\n3. MRI showing solitary ring-enhancing lesion in corpus callosum\n4. Subacute neurological symptoms\n5. The presence of lymphocytic pleocytosis in CSF\n\nPCNSL is an AIDS-defining illness that typically occurs in severely immunocompromised patients and is almost always associated with EBV infection in HIV-positive individuals. The MRI findings of a solitary, weakly enhancing lesion in the corpus callosum is particularly characteristic of PCNSL.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "Enfuvirtide (T-20, brand name Fuzeon) is the medication that acts on the gp41 subunit of the HIV envelope glycoprotein. It is a fusion inhibitor that prevents HIV from entering CD4+ T cells by blocking the conformational change of gp41 necessary for viral fusion with the cell membrane. However, it's important to note that enfuvirtide is not typically used as first-line therapy due to its need for twice-daily subcutaneous injection and is usually reserved for salvage therapy in treatment-experienced patients with drug resistance.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV screening test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Based on the symptoms (fever, malaise, diarrhea), lymphadenopathy, and the relatively high CD4 count (650/mm3), this patient is most likely in the Acute HIV Infection stage, also known as Acute Retroviral Syndrome or Primary HIV Infection. This typically occurs 2-4 weeks after initial HIV exposure and presents with flu-like symptoms. The high CD4 count is consistent with early infection, as significant CD4 depletion has not yet occurred.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 57-year-old HIV-positive male with a history of intravenous drug abuse presents to the emergency room complaining of arm swelling. He reports that he developed progressively worsening swelling and tenderness over the right antecubital fossa three days prior. He recently returned from a trip to Nicaragua. His past medical history is notable for an anaphylactoid reaction to vancomycin. His temperature is 101.4\u00b0F (38.6\u00b0C), blood pressure is 140/70 mmHg, pulse is 110/min, and respirations are 20/min. Physical examination reveals an erythematous, fluctuant, and tender mass overlying the right antecubital fossa. Multiple injection marks are noted across both upper extremities. He undergoes incision and drainage and is started on an antibiotic that targets the 50S ribosome. He is discharged with plans to follow up in one week. However, five days later he presents to the same emergency room complaining of abdominal cramps and watery diarrhea. What class of pathogens is most likely responsible for this patient\u2019s current symptoms?",
    "answer": "Given the clinical scenario, this patient most likely has Clostridioides difficile (C. diff) infection. This conclusion is based on:\n\n1. Recent antibiotic use - he was likely treated with clindamycin (a 50S ribosomal subunit inhibitor) for his skin/soft tissue infection\n2. Development of watery diarrhea and abdominal cramps within days of antibiotic treatment\n3. Clindamycin is particularly notorious for causing C. diff infections\n\nClostridioides difficile is an anaerobic, gram-positive, spore-forming bacterium that can cause antibiotic-associated diarrhea. The risk is higher in:\n- Immunocompromised patients (like this HIV-positive patient)\n- Those receiving broad-spectrum antibiotics\n- Recent healthcare exposure\n- Advanced age\n\nEarly recognition and appropriate treatment (stopping the offending antibiotic if possible and starting oral vancomycin or fidaxomicin) is important to prevent complications.",
    "true_answer": "Gram-positive bacillus is most likely responsible for this patient\u2019s current symptoms."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "The most likely target would be gp120, which is a surface glycoprotein on the HIV envelope.\n\nThis is because:\n1. gp120 is exposed on the viral surface and accessible to antibodies\n2. It plays a crucial role in viral entry by binding to CD4 receptors\n3. It's one of the main targets of neutralizing antibodies in natural infection\n4. It's commonly targeted in HIV vaccine and therapeutic antibody development\n\ngp120 is generally considered a better target than other viral proteins like p24 (internal capsid protein) or reverse transcriptase (inside the virus) which aren't accessible to antibodies when the virus is intact.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "The most likely causal organism is Aspergillus fumigatus. The clinical presentation (fever, hemoptysis), radiographic finding (fibrocavitary lesion), and most importantly, the microscopic finding of septate hyphae branching at acute angles (approximately 45 degrees) are classic for invasive pulmonary aspergillosis. This is a significant opportunistic infection in HIV-positive patients, particularly those with low CD4 counts.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "The greatest risk when adding valganciclovir to this patient's current regimen is bone marrow suppression (particularly neutropenia and anemia). This risk is especially significant because the patient is already taking zidovudine (AZT), which is also known to cause bone marrow suppression.\n\nThe overlapping toxicity profiles of these two medications (valganciclovir and zidovudine) can lead to:\n1. Worsened anemia (the patient already shows pallor)\n2. Increased risk of neutropenia\n3. Potentially increased risk of infections due to neutropenia\n\nClose monitoring of complete blood counts (CBC) would be necessary for this patient, and dose adjustments might be required if significant bone marrow suppression occurs.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "For infants born to HIV-positive mothers, the most appropriate diagnostic test is HIV DNA PCR testing. This test should be performed at:\n- 14-21 days of life\n- 1-2 months\n- 4-6 months\n\nHIV antibody testing is NOT appropriate for newborns because maternal antibodies cross the placenta and can persist in the infant for up to 18 months, leading to false-positive results. HIV DNA PCR testing directly detects the presence of viral genetic material, making it the preferred method for early infant diagnosis.\n\nA negative HIV DNA PCR result from tests performed at these intervals, along with no breastfeeding, can reliably rule out HIV infection in exposed infants.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "The most appropriate next step would be to:\n\n1. Strongly counsel the patient about the importance of disclosing his HIV status to his wife, as she is at risk and needs testing\n\n2. Inform him that while his medical information is confidential, many states have legal requirements for HIV-positive individuals to inform sexual partners\n\n3. Explain that if he refuses to inform his wife, public health authorities may need to be notified to assist with partner notification while maintaining his confidentiality\n\nThe physician cannot directly tell the wife due to HIPAA regulations and patient confidentiality, even though she is also a patient. However, the public health risk must be addressed through proper channels.\n\nThe focus should be on working with the patient to ensure appropriate disclosure while maintaining trust in the physician-patient relationship and following legal requirements for partner notification.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Given the clinical presentation and laboratory findings, this patient has acute pancreatitis. Among HIV patients on antiretroviral therapy (ART), medication-induced pancreatitis is a significant consideration, particularly if the patient is taking didanosine (ddI), stavudine (d4T), or other nucleoside reverse transcriptase inhibitors (NRTIs).\n\nHowever, we don't have information about her specific HIV medications. Other important causes to consider in this case include:\n\n1. Alcohol use (though described as moderate)\n2. HIV infection itself\n3. Hypertriglyceridemia (which can be associated with both HIV infection and ART)\n\nWithout knowing her specific HIV medications, triglyceride levels, and more details about her alcohol consumption, medication-induced pancreatitis from ART would be the most likely etiology given:\n- Recent HIV diagnosis with presumed initiation of ART\n- Absence of gallstones on CT\n- Known association between certain HIV medications and pancreatitis\n\nThe next steps should include:\n- Reviewing her specific HIV medications\n- Checking triglyceride levels\n- More detailed alcohol history\n- Considering temporary discontinuation of suspected causative medications in consultation with her HIV specialist",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " What would be the best methodological approach to study microRNAs as therapeutic targets in HIV patients?",
    "answer": "For studying microRNAs as therapeutic targets in HIV patients, I would recommend this basic methodological approach:\n\n1. Initial screening:\n- Perform RNA sequencing to identify differentially expressed microRNAs in HIV+ vs healthy controls\n- Focus on microRNAs known to be involved in immune regulation and viral replication\n\n2. Validation:\n- qRT-PCR validation of candidate microRNAs\n- Analysis in different patient cohorts (treatment-naive, treated, elite controllers)\n\n3. Functional studies:\n- In vitro experiments using primary CD4+ T cells\n- MicroRNA inhibition/overexpression studies\n- Assessment of viral replication and immune responses\n\n4. Mechanism investigation:\n- Target prediction and validation\n- Pathway analysis\n- Protein-level confirmation\n\n5. Therapeutic potential:\n- Test microRNA mimics or inhibitors in vitro\n- Evaluate delivery methods\n- Consider safety aspects\n\nRemember to include appropriate controls and use multiple technical/biological replicates throughout the process.",
    "true_answer": "To study microRNAs as therapeutic targets in HIV patients, the best methodological approach would likely include a combination of in vitro experiments, in vivo animal models, and clinical trials . Initial in vitro experiments would involve the use of HIV-infected cell lines or primary cells to study the function and expression of specific microRNAs in relation to HIV replication and pathogenesis . This research would provide insights into the potential roles of microRNAs in HIV infection and help identify candidate microRNAs for therapeutic targeting . Next, in vivo animal models, such as humanized mice, should be employed to study the effects of modulating specific microRNAs on HIV infection and disease progression . These models would help evaluate the safety and efficacy of potential microRNA-based therapies, as well as investigate the potential for off-target effects and immunogenicity . Techniques such as delivery of microRNA mimics or antagomirs, viral vector-mediated overexpression or knockdown, and CRISPR-Cas9 editing can be used to manipulate microRNA expression in these models  . Finally, clinical trials should be conducted to validate the safety, efficacy, and tolerability of potential microRNA-based therapies in HIV patients . These trials would involve the enrollment of HIV-positive patients to receive the experimental treatment(s) under controlled conditions, with rigorous monitoring of viral load, treatment-related adverse events, immune function, and other relevant parameters . The results of these clinical trials would be instrumental in determining the clinical feasibility of microRNA-based therapies for treating HIV infections ."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "DNA methylation changes have been observed in HIV infection, though our understanding is still evolving. In latent HIV-1, hypermethylation of the viral promoter region (5' LTR) is associated with viral silencing and maintenance of latency. During active infection, global DNA methylation patterns are altered, with studies showing both hyper- and hypomethylation of host genes involved in immune response and inflammation. However, many details about specific methylation profiles and their clinical significance remain under investigation. I would be cautious about making more specific claims without citing recent research, as this is an active area of study.",
    "true_answer": "According to the scientific literature, DNA methylation significantly influences HIV-1 pathogenesis. In active infection, global changes in host cell DNA methylation are evident, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]